索利那新联合米拉贝隆治疗女性膀胱过度活动症的临床效果

Clinical effect of Solinaxine combined with Mirabelone in the treatment of female overactive bladder

目的探究索利那新联合米拉贝隆治疗女性膀胱过度活动症(OAB)的效果。方法选取2020年1月至2023年2月九江市第一人民医院收治的60例OAB女性患者作为研究对象,按随机数字表法将其分为对照组与试验组,每组各30例。对照组患者采用索利那新治疗,试验组患者在对照组的基础上加用米拉贝隆治疗。比较两组患者的临床疗效、排尿情况、膀胱过度活动症评分(OABSS)、不良反应。结果试验组患者治疗12周的总有效率高于对照组,差异有统计学意义(P<0.05)。两组患者治疗4、8、12周的每天排尿次数、夜尿、尿急、急迫性尿失禁次数均少于治疗前,治疗12周的每天排尿次数、夜尿、尿急、急迫性尿失禁次数少于治疗4、8周,治疗8周的每天排尿次数、夜尿、尿急、急迫性尿失禁次数少于治疗4周,差异有统计学意义(P<0.05);试验组患者治疗4、8、12周的每天排尿次数、夜尿、尿急、急迫性尿失禁次数均少于对照组,差异有统计学意义(P<0.05)。两组患者治疗4、8、12周的OABSS评分低于治疗前,治疗12周的OABSS评分低于治疗4、8周,治疗8周的OABSS评分低于治疗4周,差异有统计学意义(P<0.05);试验组患者治疗4、8、12周的OABSS评分低于对照组,差异有统计学意义(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论女性OAB患者采用米拉贝隆、索利那新联合治疗可减轻病症,提高疗效,且不增加不良反应。

Objective To explore the effect of Solinaxine combined with Mirabelone in the treatment of female overactive bladder(OAB).Methods A total of 60 female patients with OAB admitted to Jiujiang No.1 People's Hospital from January 2020 to February 2023 were selected as research objects and divided into the control group and the experimental group with 30 cases in each group according to random number table method.The control group was treated with Solinaxine,and the experimental group was treated with Mirabelone on the basis of the control group.The clinical efficacy,urinary status,overactive bladder syndrome score(OABSS)and adverse reactions were compared between the two groups.Results After 12 weeks of treatment,the total effective rate of experimental group was higher than that of control group,and the difference was statistically significant(P<0.05).The frequency of daily urination,night urination,urgent urination and urge incontinence in the two groups at 4,8 and 12 weeks of treatment were all less than before treatment,the frequency of daily urination,night urination,urgent urination and urge incontinence at 12 weeks of treatment were less than those at 4 and 8 weeks of treatment,the frequency of daily urination,night urination,urgent urination and urge incontinence at 8 weeks of treatment were less than those at 4 weeks of treatment,the differences were statistically significant(P<0.05).The frequency of daily urination,nocturnal urination,urgent urination and urge incontinence in experimental group were less than those in control group at 4,8 and 12 weeks after treatment,and the differences were statistically significant(P<0.05).The OABSS scores at 4,8 and 12 weeks of treatment were lower than before treatment,the OABSS scores at 12 weeks of treatment were lower than those at 4 and 8 weeks of treatment,and the OABSS scores at 8 weeks of treatment were lower than those at 4 weeks of treatment,with statistical significance(P<0.05).The OABSS scores of experimental group were lower than those of control group at 4,8 and 12 weeks after treatment,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The combined treatment of Mirabelone and Solinaxine in female OAB patients can reduce the symptoms,improve the efficacy,and do not increase the adverse reactions.